Breaking News

Over a quarter ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Upgrade
Hikma upgraded to Overweight from Neutral at JPMorgan » 06:02
04/02/20
04/02
06:02
04/02/20
06:02
HKMPY

Use HKMPF

$0.00 /

+ (+0.00%)

JPMorgan analyst James…

JPMorgan analyst James Gordon upgraded Hikma Pharmaceuticals to Overweight from Neutral with a EUR 2,400 price target. The Vascepa patent win could double the company's annual earnings growth, says the analyst.

ShowHide Related Items >><<
HKMPY Use HKMPF
$0.00 /

+ (+0.00%)

02/26/20 H.C. Wainwright
H.C. Wainwright reiterates $51 price target on Amarin shares post Q4 results
On The Fly
Amarin slides despite fourth quarter beat on strong Vascepa demand » 11:19
02/26/20
02/26
11:19
02/26/20
11:19
TEVA

Teva

$13.08 /

-0.17 (-1.28%)

, HKMPF

Hikma Pharmaceuticals

$0.00 /

+ (+0.00%)

, HKMPY

Use HKMPF

$0.00 /

+ (+0.00%)

, RDY

Dr. Reddy's

$43.14 /

+0.44 (+1.03%)

, AMRN

Amarin

$16.44 /

-1.1 (-6.27%)

Shares of Amarin (AMRN)…

Open Full Text

ShowHide Related Items >><<
TEVA Teva
$13.08 /

-0.17 (-1.28%)

02/26/20 H.C. Wainwright
H.C. Wainwright reiterates $51 price target on Amarin shares post Q4 results
02/25/20 Wells Fargo
Emergent BioSolutions price target raised to $75 from $66 at Wells Fargo
02/24/20 Edward Jones
Teva downgraded to Sell from Hold at Edward Jones
02/17/20 UBS
Teva price target raised to $14 from $8 at UBS
HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

01/29/20 Jefferies
Jefferies confident Amarin will win patent trial, sees up to 20% rally
HKMPY Use HKMPF
$0.00 /

+ (+0.00%)

03/19/19 Citi
Hikma upgraded to Buy from Neutral at Citi
RDY Dr. Reddy's
$43.14 /

+0.44 (+1.03%)

01/28/20 CLSA
Dr. Reddy's downgraded to Outperform from Buy at CLSA
01/27/20 CLSA
Dr. Reddy's downgraded to Outperform from Buy at CLSA
AMRN Amarin
$16.44 /

-1.1 (-6.27%)

02/26/20 JPMorgan
Amarin shares 'more interesting' after recent selloff, says JPMorgan
02/26/20 Citi
Amarin shares can rally 20% on litigation win in March, say Citi
02/18/20
Fly Intel: Top five analyst upgrades
Recommendations
H.C. Wainwright reiterates $51 price target on Amarin shares post Q4 results » 07:20
02/26/20
02/26
07:20
02/26/20
07:20
AMRN

Amarin

$17.54 /

-0.05 (-0.28%)

, RDY

Dr. Reddy's

$42.70 /

-0.89 (-2.04%)

, HKMPY

Use HKMPF

$0.00 /

+ (+0.00%)

, TEVA

Teva

$13.25 /

+0.55 (+4.33%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Andrew Fein reiterates a Buy rating on Amarin (AMRN) with a $51 price target following the company's Q4 results. Amarin has asserted its confidence both in its intellecutal property and its intention to vigorously defend its patents, Fein tells investors in a research note. The analyst points out that two of the original four Abbreviated New Drug Application filers currently remain, Dr. Reddy's (RDY) and Hikma (HKMPY), while Teva (TEVA) has settled with Amarin to enter the market in August 2029 and Apotex has determined not to litigate. Fein continues to believe in the feasibility of settlement with a court decision expected in March. Meanwhile, Vascepa's positive commercial traction as an omega-3 therapeutic "represents the tip of the iceberg for the treatment," the analyst writes in a research note.

ShowHide Related Items >><<
AMRN Amarin
$17.54 /

-0.05 (-0.28%)

02/26/20 Citi
Amarin shares can rally 20% on litigation win in March, say Citi
02/18/20
Fly Intel: Top five analyst upgrades
02/18/20 Citi
Citi upgrades Amarin to Buy from Neutral after 27% selloff since November
02/18/20 Citi
Amarin upgraded to Buy from Neutral at Citi
RDY Dr. Reddy's
$42.70 /

-0.89 (-2.04%)

01/29/20 Jefferies
Jefferies confident Amarin will win patent trial, sees up to 20% rally
01/28/20 CLSA
Dr. Reddy's downgraded to Outperform from Buy at CLSA
01/27/20 CLSA
Dr. Reddy's downgraded to Outperform from Buy at CLSA
01/16/20 Jefferies
Amarin in 'good position' as 'heated' patent trial continues, says Jefferies
HKMPY Use HKMPF
$0.00 /

+ (+0.00%)

03/19/19 Citi
Hikma upgraded to Buy from Neutral at Citi
TEVA Teva
$13.25 /

+0.55 (+4.33%)

02/25/20 Wells Fargo
Emergent BioSolutions price target raised to $75 from $66 at Wells Fargo
02/24/20 Edward Jones
Teva downgraded to Sell from Hold at Edward Jones
02/17/20 UBS
Teva price target raised to $14 from $8 at UBS
02/12/20 Cantor Fitzgerald
Teva price target raised to $15 from $9 at Cantor Fitzgerald
Conference/Events
Hikma participates in a conference call with JPMorgan » 08:25
09/23/19
09/23
08:25
09/23/19
08:25
HKMPY

Use HKMPF

$0.00 /

+ (+0.00%)

European Pharma Equity…

European Pharma Equity Analyst Gordon holds a conference call with CEO Olafsson on September 23 at 9 am.

ShowHide Related Items >><<
HKMPY Use HKMPF
$0.00 /

+ (+0.00%)

03/19/19 Citi
Hikma upgraded to Buy from Neutral at Citi
Conference/Events
Hikma participates in a conference call with JPMorgan » 04:55
09/23/19
09/23
04:55
09/23/19
04:55
HKMPY

Use HKMPF

$0.00 /

+ (+0.00%)

European Pharma Equity…

European Pharma Equity Analyst Gordon holds a conference call with CEO Olafsson on September 23 at 9 am.

ShowHide Related Items >><<
HKMPY Use HKMPF
$0.00 /

+ (+0.00%)

03/19/19 Citi
Hikma upgraded to Buy from Neutral at Citi
Conference/Events
Hikma participates in a conference call with JPMorgan » 09:33
09/17/19
09/17
09:33
09/17/19
09:33
HKMPY

Use HKMPF

$0.00 /

+ (+0.00%)

European Pharma Equity…

European Pharma Equity Analyst Gordon holds a conference call with CEO Olafsson on September 23 at 9 am.

ShowHide Related Items >><<
HKMPY Use HKMPF
$0.00 /

+ (+0.00%)

03/19/19 Citi
Hikma upgraded to Buy from Neutral at Citi

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.